Structure Therapeutics To Participate In Two Upcoming Healthcare Investor Conferences

2025-09-02 08:46:15

(MENAFN- GlobeNewsWire - Nasdaq) SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in September.

Cantor Global Healthcare Conference
	Format:	Fireside chat and 1x1 meetings
	Date/time:	Wednesday, September 3 at 3:55 p.m. ET
	Location:	New York, NY

Morgan Stanley 23rd Annual Global Healthcare Conference
	Format:	Fireside chat and 1x1 meetings
	Date/time:	Wednesday, September 10 at 10:45 a.m. ET
	Location:	New York, NY

The live and archived webcasts will be accessible from the company's website at and replays will be available for 90 days.

About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit .

Investors:
Danielle Keatley
Structure Therapeutics Inc.
...

Media:
Dan Budwick
1AB
Dan@1abmedia.com

MENAFN02092025004107003653ID1110005844

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.